Avenge Bio
Por um escritor misterioso
Descrição
Avenge Bio was founded by an experienced team of proven biotech executives to develop transformative therapeutics which can potentially eradicate intractable solid tumors.
Avenge Bio is developing our proprietary, allogeneic LOCOcyteTM platform for precision delivery of cytokines and other highly potent immunomodulatory molecules for a controlled period of time. Through this approach we are able to generate robust, local and systemic anti-tumor immune responses, without the toxicities associated with traditional immunotherapies.
The LOCOcyteTM platform was developed from extensive research and experience of Dr. Omid Veiseh at Rice University and supported by Longitude Capital, CAM Capital, Perceptive Xontogeny, Rock Springs, Pappas Capital, and other leading healthcare investors. Together we are using the strength and efficiency of our platform to create a broad pipeline of therapeutics that target a wide range of difficult to treat solid tumors.
Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors
Michael Heffernan on LinkedIn: I am excited to announce the closing of Avenge Bio's $45 million Series A…
New pinhead-sized beads kill ovarian, colorectal cancers by producing interleukin-2: mouse study
avengebio (@AvengeBio) / X
Avenge Bio
Douglas Carlson on LinkedIn: Avenge Bio Announces Dosing of First Patient in Phase 1/2 Clinical Trial…
avengebio (@AvengeBio) / X
Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors
Avenge Bio Closes $45 Million Series A Financing
Zeke Johnston - Senior Director, External Manufacturing & Supply Chain at Avenge Bio
Sara Kalb - Research Associate - Avenge Bio
Branding Process, Monderer Design
MartialArts Reigns (on WEBCOMICS, link in bio, C.0.D.E of Starter Perk
de
por adulto (o preço varia de acordo com o tamanho do grupo)
